A fluorescent nanoprobe is designed for the determination of carbamazepine (CBZ) in exhaled breath condensate (EBC) of patients receiving CBZ. The probe consists of copper nanoclusters (Cu NCs) coated with cetyl trimethylammonium bromide. The interaction of probe with CBZ results in blocking non-radiative e − /h + recombination defect sites on the surface of Cu NCs and consequently enhancing the blue-green fluorescence of Cu NCs (excitation/emission wavelengths: 290/480 nm). The experimental conditions were optimized using a response surface methodology (central composite design). Under the optimized conditions, the calibration plot is linear in the 0.2 to 20 μg mL −1 CBZ concentration range and the detection limit is as low as 0.08 μg mL −1
Introduction
Carbamazepine is widely used for the therapy of patients with partial and generalized tonic-clonic epilepsy and psychiatric diseases [1] . So far, various methods, such as liquid chromatography-electrospray ionization mass spectrometry method (LC-EIA-MS) in serum samples [2] , LC-MS-MS method in whole blood, serum and plasma [3] , ion mobility spectrometry in formulation samples [4] , stacking capillary electrophoresis method in serum Electronic supplementary material The online version of this article (https://doi.org/10.1007/s00604-019-3278-z) contains supplementary material, which is available to authorized users.
samples [5] , high-performance liquid chromatographydiode array detection assay after a simple sample preparation method by a packed sorbent in plasma samples [6] , online solid phase extraction -LC coupled with high resolution mass spectrum under targeted MS/MS analysis mode in serum sample [7] , and a gas chromatography method [8] have been developed for the determination of CBZ. Although the advantages of such methods are undeniable, most of these techniques need a sample preparation procedure to remove matrix components or a derivatization step before analysis and also a labelled internal standard. So, development of an easy-to-use method that can be applied for off-and on-line determination of drugs concentrations in biological samples has always been of interest in bioanalytical and clinical applications. It is important to note that the assay of biomolecules should be fast, cost-effective, selective, and sensitive. For this purpose, increasing attention has been focused on the construction of fluorescent nanoprobes for drugs [9] . Quantum dots (QDs) and nanoclusters (NCs) with particular photophysical and photochemical properties, such as high luminescence intensity, stability and efficiency, narrow, and tunable spectrum according to their size and material composition, good solubility and biocompatibility, low toxicity, can offer significant advantages for biosensing [10, 11] . However, to the best of our knowledge, QDs and/or NCs as an optical nanoprobe are rarely employed in the determination of CBZ and there is only one report in the literature for the detection of CBZ. Ma et al. [12] developed a fluorescent probe based on Ndoped carbon dots and used to the determination of CBZ in tablet and human urine spiked samples. They illustrated that the presence of CBZ in the range of 10-90 μg mL −1 result in fluorescence quenching of QDs. The detection limit was 1.93 μg mL −1 [12] .
Exhaled breath condensate (EBC) as a biological sample was chosen for this study since it possesses a number of advantages over other biological samples [13] . The collection of EBC, which has been used since the 1980s [14] , are very simple and repeatable method without any side effect or any appreciable discomfort for the EBC sample donors [15] . EBC also have a few numbers of interfering compounds compared with other matrices including blood, plasma, sputum, and urine [16] . Furthermore, the EBC collection can be repeated as often as required without any variation in the fluids on the lung surfaces [17] . The analysis of drugs in EBC is a promising process that has attracted a lot of attention [18] [19] [20] .
Herein, to continue our research works on EBC [18] [19] [20] , we synthesize Cu NCs coated with cetyl trimethylammonium bromide (CTAB) and use them for the developing an effective nanoprobe with good selectivity and sensitivity for determination of CBZ level in EBC samples. The detection mechanism is based on the blocking non-radiative e − /h + recombination defect sites on the surface of the NCs and improving the fluorescence intensity of NCs proportional with CBZ adding. For reaching better analytical figures of merit for the nanoprobe, the experimental conditions were investigated by response surface methodology (RSM), which employs statistical methods to present a second-order polynomial model between independent variables and a response variable. 
Experimental

Reagents and solutions
Apparatus and software
Fluorescence intensity was measured at 25°C on an FP-750 spectrofluorometer (Jasco Corp., Japan, www.jasco.co.jp) with 20 nm band-pass in both of the excitation and emission paths and the sensitivity of medium. The instrument has a 150 W xenon lamp, dual monochromators, 1.0 cm quartz cell, Peltier thermostated single cell holder model ETC-272 (JASCO Corp., Japan), and supported with PC-based Windows® Spectra Manager TM software for JASCO Corporation. A double-beam UV-Vis spectrophotometer model UV-1800 (Shimadzu, Japan, www.shimadzu.com) with 1.0 cm quartz cells was used to record the UV-Vis absorption spectra. The pH adjustments of the used solutions were controlled using a digital pH-meter model 744 (Metrohm Ltd., Switzerland, www.metrohm.com) supplied with a glass-combined electrode. An ultrasonic bath (Alex machine, Istanbul) and An electronic analytical balance model AB204-S (Mettler Toledo, Switzerland, www.mt.com) was employed in this study. The shape and size of prepared QDs were characterized by a transmission electron microscopy model CM30 (Philips, The Netherlands, www.philips.com).
Design and analysis of the central composite experiments were performed in MINITAB (Minitab Inc. Release 17.0, www.minitab.com/en-us/products/minitab) statistical package.
Preparation of copper nanoclusters (Cu NCs)
The Cu NCs were synthesized by following method reported in the literature [21] . 10 
Sample preparation
EBC samples were collected by a lab-made cooling trap system [22] . EBC samples used for method validation were a pool of samples collected from healthy subjects. EBC samples were directly analyzed without any pretreatment. Patient EBC samples were collected from four patients after oral administration of CBZ. Sample donors signed a consent form approved by the Ethics Committee of National Institute for Medical Research Development (approved No. IR NIMAD REC 1396 356).
General procedure
Fluorescence detection was made in a 2 mL vial by a batch method. In brief, 50 μL of 0.1 mol L −1 phosphate buffer (pH 5.0), and 50 μL of 0.5 mg L −1 Cu-NCs were added into the vial. Afterwards, a proper volume of CBZ standard solution in the range of 0.2 to 20 μg mL −1 was added and the volume was set in 0.5 mL with deionized water. To prevent a matrix effect on the validation data, EBC samples were used to validate the fluorimetric determination method. For this purpose, the EBC samples were collected from healthy subjects, spiked with proper aliquots of standard CBZ solution. After 10 min sonication, the fluorescence intensity was recorded at λ em = 480 nm after excitation at 290 nm and used as an analytical signal.
Real sample analysis
EBC samples were obtained from four subjects who had taken CBZ. 0.25 mL of EBC samples directly (without any preparation) added into a 2 mL vial containing 50 μL of 0.1 mol L −1 phosphate buffer (pH 5.0), and 50 μL of 0.5 mg L −1 Cu-NCs.
The volume in the vial was adjusted to 0.5 mL with deionized water. Then, the solution was equilibrated for 10 min in the sonication bath at room temperature. Finally, the obtained solution was transferred into microcell and the fluorescence intensity was measured at 480 nm after excitation at 290 nm. CBZ levels in EBC of patients were also analyzed using HPLC method described in the literature [23] .
Results and discussion
Choice of nanoparticles
In order to investigate the nanoparticle's type, various nanomaterials such as Cu NCs, Zn NCs, Ag NCs and carbon QDs (CQDs) were synthesized and used for determination of CBZ in a similar condition. Fluorescence spectra of these nanomaterials in the absence and presence of CBZ (10 μg mL −1 ) are shown in Fig. 1S . As can be seen, Ag
NCs, Zn NCs, CQDs do not show any spectral changes in the presence of CBZ and only a slight interaction is observed between Cu NCs and CBZ. According to these results, in the next attempt, CTAB modified Cu NCs was used for production of an effective interaction between nanoparticles and CBZ due to non-ionic property of CBZ. The possible reason for such a large variation in fluorescence spectra of CTAB modified Cu NCs (Fig. 2S) is related to the incorporation of CBZ into the inner hydrophobic part of produced ad-micelles or hemi-micelles of CTAB on the surface of NCs and changing in environmental conditions of them that produce a suitable assemble and change the intrinsic fluorescence of nanoparticles.
Characterization of Cu-NCs
The shape and size of synthesized NCs were characterized by transmission electron microscopy (TEM). As can be seen in Fig. 1 , the NCs are uniform in size and exhibit a nearly spherical shape with an average size of <8 nm.
Detection mechanism
In the high concentration of prepared NCs and under single wavelength excitation at 290 nm, the Cu-NCs shows two fluorescent bands centred at 415 and 480 nm (Fig. 2) . According to previous studies, the dual fluorescent bands of the QDs can be attributed to different surface states [24] . It should be noted that the low concentration of NCs was used for detection of CBZ; thus, in the absence of CBZ, the synthesized NCs emits only a well-resolved emission peak at 415 nm. Upon the addition of CBZ, the fluorescence spectra show a new emission peak centred at 480 nm, whereas the intensity at 415 nm of the NCs remains relatively unchanged. The fluorescence spectra of the designed nanoprobe after addition of various concentration of CBZ is shown in Fig. 3 . As can be seen, the fluorescence intensity is proportional to the amount of CBZ, ranging from 0.2 to 20 μg mL
, which can be used for the quantification of CBZ.
Two classes of fluorescence emission mechanisms have been reported for QDs and/or NCs in the literature: (i) the bandgap transitions; (ii) transitions arising from surface defects in QDs; generally, any sites that result in surface energy traps [25] . Surface modification of QDs and interaction with surrounding species may change their chemical and optical properties [26, 27] and cause to some effects including: (i) activation of fluorescence by enhancement of excitonic and defect emission by blocking non-radiative electron/ hole (e − / h + ) recombination defect sites on the surface of the QDs, (ii) creation of new traps on the surface of the QDs causing appearance of new emission peaks, (iii) enhancement of the selectivity and efficiency of light-induced reactions done on the surface of QDs [28] , (iv) it may quench QDs fluorescence through two possible pathways: fluorescence resonance energy transfer (FRET) and the common charge transfer [29] .
In this study, CTAB was grafted on the Cu-NCs surface and served as the linking reagent for linking of CBZ. We conjectured that the interaction of Cu-NCs with CBZ resulted in blocking non-radiative e − /h + recombination defect sites on the NCs surface and consequently enhancing the fluorescence intensity of NCs.
Optimization of reaction conditions by a central composite design (CCD)
RSM was used to investigate the influence of several reaction factors that affect the determination of CBZ by considering the interactive effects of independent factors (pH, the probe and phosphate buffer concentration, and the reaction time of the system, in this case). , and time = 10 min.
Interference study
The selectivity of the nanoprobe toward analyte in the presence of various anions, cations and possible co-administered drugs is also investigated by measuring the fluorescence intensity upon the addition of various concentrations of , and time = 10 min, λ ex /λ em : 290/ 480 nm Fig. 1 TEM image of the CTAB coated Cu-NCs interferents. From a practical viewpoint, CBZ is used as a single drug the treatment of most forms of epilepsy and the drug of first choice in the germinal neural-gia [30] and as a combined drug regimen in bipolar mania, restless legs syndrome and schizophrenia [31] . The most frequently coprescribed drugs with CBZ include the antiepileptic drugs and we tested the interference of available antiepileptic drugs in this work. The results are presented in Table 1 . The results show that the presence of anions and cations, such as Na . The results are shown in Table 2 . As can be seen naproxen, chlordiazepoxide, glibenclamide, oxazepam, acetaminophen, celecoxib, and clonazepam interfere with CBZ determination when they are present in 25 times of the concentration rations of interfering substance to CBZ. It means that interfering concentration for these drugs is about 12.5 μg.mL −1 which is much higher than concentration founded for the drugs in EBC. As limited data are published for concentration range of drugs in EBC samples, we checked this claim for a safe drug e.g. acetaminophen. For this purpose, a healthy volunteer is given 1 g of acetaminophen daily for 3 days. After this time, the concentration of acetaminophen in EBC of investigated subject is found to be <0.1 μg.mL −1 which is below its tolerable level.
These results demonstrate that the presented nanoprobe has good selectivity for CBZ detection.
Analytical figures of merit
In the optimum conditions described, a linear relationship (R 2 = 0.993) between the CBZ concentration and fluorescence intensity was observed at the concentration range of 0.2-20 μg mL −1 (excitation/emission wavelength: 290/480 nm).
The regression equation was ΔI F = 21.626 C CBZ + 18.691, where ΔI F is the response intensity difference between blank (nanoprobe in the absence of CBZ) and sample solution (nanoprobe in the presence of CBZ) in an arbitrary unit, and C CBZ is the concentration of CBZ in μg mL −1 (Fig. 4) . The detection limit of the present method for CBZ determination was computed after the employing of the mentioned general procedure for blank solutions. The detection limit and quantification limit, defined as 3 S b /m, and 10 S b /m (where S b is the standard deviation of the blank and m is the slope of the calibration plot) are 0.08 μg mL −1 and 0.20 μg mL
, respectively. The precision of the method was investigated by replicating the CBZ determination during the course of experimentation on different days and on the same day. The intra-day and inter- Table 3 . As can be seen, the LOD of method is good and comparable with that of other reported methods. Also, the method is relatively rapid due to direct analysis and no need for any sample preparation procedure prior to analysis. Whereas, most of the reported methods applied for determination of CBZ used a liquid or solid-phase extraction for cleanup and analyte preconcentration before the sample analysis. These results show that the presented nanoprobe has good performance for CBZ determination. However, there are some issues related to the used nanoprobe and EBC which limit their application. These issues include (i) poor storage stability of nanoprobe over longer periods of time due to their small size (with an average size of <8 nm) and large surface area which can lead to particle-particle aggregation and making physical handling of nanoparticles difficult in liquid form; and (ii) some limitations associated with the EBC samples including adsorption of analytes to the surface of the collection setup, patient-to-patient variability in EBC volume and the effect of lung function on the collected sample volume and unavailability of an accepted dilution marker for EBC samples. These limitations and some solutions to overcome them are discussed in reference [13] in details.
EBC sample analysis
To further investigate the applicability of the nanoprobe on real samples, the probe was used to detect CBZ in EBC of patients receiving CBZ. All samples were taken 1 h after taking the last dose. The results of the analysis are summarized in Table 4 . The accuracy of the method was approved by HPLC measurement as a reference method applied to the same EBC sample [32] . Using the paired t-test (2-tail) shows no significant difference at 95% confidence level demonstrating the method is accurate and has a great potential for determination of CBZ in EBC samples.
Conclusions
A sensitive nanoprobe for CBZ determination has been developed. The nanoprobe takes advantage of the high sensitivity and the high stability of the CTAB-coated NCs toward CBZ to provide an effective platform for reliable determination of CBZ. The nanoprobe was successfully used for the determination of CBZ in EBC of patients receiving CBZ and an average level of 0.47 μg mL −1 was reported. Reliability and no practical limitation of the method makes it a promising system for routine quantification of CBZ in clinical practices. This is the first report on CBZ levels in EBC and these types of CBZ quantifications using a non-invasive sampling method are highly in demand in dosage adjustment of CBZ.
